Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senaparib plus bevacizumab as first-line maintenance in HR-proficient ovarian cancer
ChiCTR2500109579Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of senaparib and bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-Free Survival (PFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
senaparibbevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2500109579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109579.